Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Subscribe To Our Newsletter & Stay Updated
